For cancer immunotherapy to work better, the tumor microenvironment must sustain organized immune activity — not just recruit immune cells, but keep them coordinated and functional. New mechanistic evidence pinpoints a specific dendritic cell population as the master regulator of this process, potentially redefining how clinicians think about enhancing immunotherapy response.
Published in Science, the study combined spatial transcriptomics with multiplex imaging across human tumor samples and a mouse non-small cell lung cancer model to dissect how tertiary lymphoid structures (TLS) — organized immune aggregates that form within tumors — are built and maintained. The research found that CCR7+ mature type 1 conventional dendritic cells (cDC1s) are central to TLS biology across two distinct phases. Early TLS formation depends on IFN-γ-driven cDC1 maturation, migration to tumor-draining lymph nodes, and subsequent T cell recruitment into the tumor. Later, as tumors progress, TLS maintenance shifts to a locally autonomous program: cDC1s accumulate in intratumoral CCL19+ stromal hubs where simultaneous MHC-I and MHC-II antigen presentation, alongside CD40 signaling, sustains germinal center activity, T follicular helper cell populations, and tumor-specific IgG antibody production.
TLS have been linked to improved outcomes in multiple cancer types and to immunotherapy responsiveness, but the field has lacked a mechanistic anchor for their persistence. This study provides that anchor — and it is the cDC1 population. What makes this finding notable is the two-phase model: the same cell type controls initiation through systemic lymph node crosstalk and maintenance through a self-contained intratumoral niche. This structural insight is a meaningful advance over prior correlative observations. Key caveats apply: the mechanistic work was conducted in a single mouse lung cancer model, and translating cDC1 targeting strategies to human patients will require validation in larger, histologically diverse cohorts. Still, the identification of CCL19 stromal hubs as TLS maintenance zones opens a concrete therapeutic angle — boosting cDC1 function or seeding cDC1s into tumors could represent a rational strategy to amplify or restore TLS-dependent antitumor immunity, particularly in immunotherapy-resistant settings.